Quince Therapeutics Inc

NASDAQ:QNCXUnited States

Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, EryDex, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules, as well as biologics.

Contact Information

Headquarters

601 Gateway Boulevard, Suite 1250SOUTH SAN FRANCISCO, CA, United States 94080

Phone

415-910-5717

Fax

302-655-5049

Executives

Independent Chairman of the Board

David Lamond

President

Charles Ryan

Chief Executive Officer, Chief Medical Officer, Director

Dirk Thye

Chief Operating Officer, Chief Business Officer, Principal Financial Officer and Principal Accounting

Brendan Hannah

Lead Independent Director

Una Ryan